Tonix Pharmaceuticals Holding Corp. (TNXP)

Compare

20.32

+0.15

+(0.72%)

As of 11:03:39 AM EDT. Market Open.

Tonix’s Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year

CHATHAM, NJ / ACCESS Newswire / March 31, 2025 /This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations ...

ACCESS Newswire 4 hours ago

TNXP
+0.72%
New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc.

Sponsored by The Sustainable Green Team (OTC: SGTM), featuring Kevin Harrington - the ORIGINAL Shark from Shark Tank NEW YORK CITY, NEW YORK / ACCESS Newswire / March 29, 2025 /New to The Street, the nation's leading syndicated business television ...

ACCESS Newswire 2 days ago

BIVI

TNXP
+0.72%
SGTM
Tonix Pharmaceuticals Announces Presentation at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

CHATHAM, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer, will present a poster at the AAPM 2025 Annual Meeting, PainConnect, in Austin, Texas on April 5, 2025, at 11:45 a.m. CT. The meeting will take place from April 3-6, 2025. A copy of the Company’s poster will be avail

GlobeNewswire 4 days ago

TNXP
+0.72%
Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia

On track for August 15, 2025 FDA PDUFA goal date TNX-102 SL is a non-opioid analgesic; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Commercial planning for TNX-102 SL underway for launch in the fourth quarter of 2025 CHATHAM, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development c

GlobeNewswire 7 days ago

TNXP
+0.72%
As Mpox Cases Spread Around the World, Tonix Pharmaceuticals’ Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread

Clade I, the culprit in the current 2025 version of global epidemic mpox, is highly transmissible and is spreading within families and among children, whereas the 2022 Clade II mpox - still spreading - infects mostly gay men CHATHAM, NJ / ACCESS Newswire ...

ACCESS Newswire 11 days ago

TNXP
+0.72%
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Company expects to have sufficient cash to fund planned operations beyond the FDA PDUFA goal date and anticipated fourth quarter 2025 launch of TNX-102 SL for fibromyalgia; $98.8 million in cash as of December 31, 2024 Announced positive topline results from Phase 1 study of TNX-1500, a next generati

GlobeNewswire 12 days ago

TNXP
+0.72%
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum, held March 13th are now available for online viewing. REGISTER NOW AT: https://bit.ly/3DIWqav The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download

GlobeNewswire 17 days ago

PDSB

TELIF

BPTSY
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025

CHATHAM, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at the 2025 BIO-Europe Spring Convention being held March 17-19, 2025, in Milan, Italy. The Company’s presentation will take place on Monday, March 17, 2025, at

GlobeNewswire 18 days ago

TNXP
+0.72%
Life Sciences Investor Forum Agenda Announced for March 13th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum March 13th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT: https://bit.ly/4hnure6 It is recommended that inve

GlobeNewswire 18 days ago

NGENF

BPTSY

HMTXF
Tonix’s TNX-1500 Shows Promise in Preventing Organ Transplant Rejections of Either Human or Pig Organs; Autoimmune Diseases Also a Target

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained ...

ACCESS Newswire 19 days ago

TNXP
+0.72%
Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th

CHATHAM, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at the Zacks SCR Life Sciences Virtual Investor Forum on Thursday, March 13, 2025, at 3:30 p.m. ET. Pre-register for Tonix’s virtual presentation at VirtualInvestorConferences.com. Thi

GlobeNewswire 20 days ago

TNXP
+0.72%
Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense Consortium (MCDC) for Development of TNX-801, the Company’s Single-Dose Mpox and Smallpox Vaccine Candidate

The World Health Organization (WHO) recently reaffirmed the spread of new clade Ib Mpox a public health emergency of international concern (PHEIC): second Mpox-related WHO PHEIC declaration in two years Clade Ib Mpox cases detected in several countries in Central and Eastern Africa as well as China, Thailand, Singapore, India, England, parts of Europe and the Middle East, Canada and the United States Tolerability of TNX‐801 vaccination in immune-compromised animal models supports clinical develo

GlobeNewswire 21 days ago

TNXP
+0.72%
Why Tonix Pharmaceuticals Holding Corp. (TNXP) Soared Last Week

We recently compiled a list of the 10 Micro-, Small-Cap Firms Were Last Week’s Top Performers. In this article, we are going to take a look at where Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) stands against the other stocks. Micro- and small-cap companies dominated the stock market last week, clocking in impressive gains on the back of […]

Insider Monkey 21 days ago

TNXP
+0.72%
^RUT
Why Tonix Pharmaceuticals Holding Corp. (TNXP) Soared on Thursday

We recently published an article titled Micro-, Small-Cap Firms Dominate Market Rally. In this article, we are going to take a look at where Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) stands against the other stocks. The stock market pulled back to the red territory on Thursday, with all major indices posting significant losses as tariff threats continued […]

Insider Monkey 23 days ago

TNXP
+0.72%
^GSPC
A 41% Surge? This Small-Cap Pharma Stock Just Shook Up the Fibromyalgia Market

A breakthrough non-opioid drug could change fibromyalgia treatment forever--investors are piling in ahead of the FDA decision.

GuruFocus.com 24 days ago

TNXP
+0.72%
Tonix Surges 31% Following Positive Phase 3 Fibromyalgia Drug Trial Results

TNX-102 SL showed statistically significant pain reduction in two randomized, double-blind studies.

GuruFocus.com 24 days ago

TNXP
+0.72%
Tonix Pharmaceuticals to Present at the 2025 Virtual Investor Summit

CHATHAM, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the 2025 Virtual Investor Summit on Tuesday, March 11, 2025, at 10:30 a.m. ET. Investors interested in arranging a meeting with the Company’s management virtually

GlobeNewswire 26 days ago

TNXP
+0.72%
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at 7th International Congress on Controversies in Fibromyalgia

TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia TNX-102 SL demonstrated statistically significant improvement in the primary endpoint of reduction in fibromyalgia pain in two double-blind randomized Phase 3 studies FDA Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia If approved by FDA, it would become the first member of a new class of

GlobeNewswire 27 days ago

TNXP
+0.72%
TNXP: PDUFA Date for TNX-102 SL in Fibromyalgia of August 15, 2025…

By David Bautz, PhD NASDAQ:TNXP READ THE FULL TNXP RESEARCH REPORT Business Update PDUFA Date of August 15, 2025 for NDA TNX-102 SL in Fibromyalgia On December 23, 2024, Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) announced that the FDA assigned a Prescription Drug User Fee Act (PDUFA) target date of August 15, 2025 for a decision on the NDA filing for TNX-102 SL for the management of

Zacks Small Cap Research last month

TNXP
+0.72%
Tonix Pharmaceuticals reports positive topline trial outcomes of TNX-1500

During the trial, TNX-1500 was administered intravenously to subjects at various dose ranges.

Clinical Trials Arena last month

TNXP
+0.72%

Performance Overview

Return	TNXP	S&P 500 (^GSPC)
YTD	-38.44%	-5.79%
1-Year	-96.66%	+5.46%
3-Year	-99.99%	+22.31%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Tonix Pharmaceuticals Holding Corp. (TNXP)

Tonix’s Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year

New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc.

Tonix Pharmaceuticals Announces Presentation at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia

As Mpox Cases Spread Around the World, Tonix Pharmaceuticals’ Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025

Life Sciences Investor Forum Agenda Announced for March 13th

Tonix’s TNX-1500 Shows Promise in Preventing Organ Transplant Rejections of Either Human or Pig Organs; Autoimmune Diseases Also a Target

Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th

Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense Consortium (MCDC) for Development of TNX-801, the Company’s Single-Dose Mpox and Smallpox Vaccine Candidate

Why Tonix Pharmaceuticals Holding Corp. (TNXP) Soared Last Week

Why Tonix Pharmaceuticals Holding Corp. (TNXP) Soared on Thursday

A 41% Surge? This Small-Cap Pharma Stock Just Shook Up the Fibromyalgia Market

Tonix Surges 31% Following Positive Phase 3 Fibromyalgia Drug Trial Results

Tonix Pharmaceuticals to Present at the 2025 Virtual Investor Summit

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at 7th International Congress on Controversies in Fibromyalgia

TNXP: PDUFA Date for TNX-102 SL in Fibromyalgia of August 15, 2025…

Tonix Pharmaceuticals reports positive topline trial outcomes of TNX-1500

Performance Overview